Advertisement

FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma


Advertisement
Get Permission

Today, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

CheckMate 649

The efficacy of the combination was evaluated in CheckMate 649 (ClinicalTrials.gov identifier: NCT02872116), a randomized, multicenter, open-label trial that enrolled 1,581 patients with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. PD-L1 combined positive score (CPS) was determined centrally using the Agilent/Dako PD-L1 IHC 28-8 pharmDx test.

Patients received nivolumab in combination with chemotherapy (n = 789) or chemotherapy alone (n = 792); study treatment was administered as follows:

  • Nivolumab at 240 mg with mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) every 2 weeks, or mFOLFOX6 every 2 weeks
  • Nivolumab at 360 mg with CapeOX (capecitabine and oxaliplatin) every 3 weeks, or CapeOX every 3 weeks.

The main efficacy outcome measures, assessed in patients with PD-L1 CPS ≥ 5 (n = 955), were progression-free survival assessed by blinded independent central review and overall survival. CheckMate 649 demonstrated a statistically significant improvement in both progression-free and overall survival for patients with PD-L1 CPS ≥ 5.

Median overall survival was 14.4 months (95% confidence interval [CI] = 13.1–16.2 months) in the nivolumab-plus-chemotherapy arm vs 11.1 months (95% CI = 10.0–12.1 months) in the chemotherapy-alone arm (hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.61–0.83, P < .0001). Median progression-free survival was 7.7 months (95% CI = 7.0–9.2 months) in the nivolumab-plus-chemotherapy arm vs 6.0 months (95% CI = 5.6–6.9 months) in the chemotherapy-alone arm (HR = 0.68, 95% CI = 0.58–0.79, P < .0001).

As an additional efficacy outcome measure, a statistically significant improvement in overall survival was also demonstrated for all randomly assigned patients (n = 1,581) irrespective of CPS, with a median overall survival of 13.8 months (95% CI = 12.6–14.6 months) in the nivolumab-plus-chemotherapy arm vs 11.6 months (95% CI = 10.9–12.5 months) in the chemotherapy-alone arm (HR = 0.80, 95% CI = 0.71–0.90, P = .0002).

The most common adverse reactions (incidence ≥ 20%) observed in patients receiving nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy were peripheral neuropathy, nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation, and musculoskeletal pain.

The recommended nivolumab dosages are:

  • 360 mg every 3 weeks in combination with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks
  • 240 mg every 2 weeks in combination with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement